PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.

Abstract The aim of the study was to test the cost-effectiveness of dasatinib compared to high-dose imatinib and nilotinib in Chinese patients who were diagnosed with imatinib-resistant chronic myeloid leukemia in the chronic phase (CML-CP).
PMID
Related Publications

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.

Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28723754
OWN - NLM
STAT- MEDLINE
DA  - 20170720
DCOM- 20170728
LR  - 20170728
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 29
DP  - 2017 Jul
TI  - An economic analysis of high-dose imatinib, dasatinib, and nilotinib for
      imatinib-resistant chronic phase chronic myeloid leukemia in China: A
      CHEERS-compliant article.
PG  - e7445
LID - 10.1097/MD.0000000000007445 [doi]
AB  - BACKGROUND: The aim of the study was to test the cost-effectiveness of dasatinib 
      compared to high-dose imatinib and nilotinib in Chinese patients who were
      diagnosed with imatinib-resistant chronic myeloid leukemia in the chronic phase
      (CML-CP). METHODS: A Markov model combined with clinical effectiveness, utility, 
      and cost data was used. The sensitivity analyses were conducted to determine the 
      robustness of the model outcomes. The impact of patient assistance programs
      (PAPs) was assessed. RESULTS: Treatment with dasatinib is expected to produce
      3.65, 0.59, and 0.15 more quality-adjusted life years (QALYs) in comparison with 
      high-dose imatinib (600 and 800 mg) and nilotinib, respectively. When a PAP was
      available, dasatinib yielded an incremental cost of $16,417 per QALY compared to 
      imatinib (600 mg) and was cost-saving compared to imatinib (800 mg) and
      nilotinib. CONCLUSION: When PAP is available in the Chinese setting, dasatinib is
      likely to be a cost-effective strategy for patients with CML-CP standard-dose
      imatinib resistance. The results should be carefully explained due to the
      assumptions and limitations used in the study.
FAU - Wu, Bin
AU  - Wu B
AD  - aMedical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital,
      South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai
      bDepartment of Pharmacy, Fujian Union Hospital, Affiliated with Fujian Medical
      University, Fujian cDepartment of Pharmacy, Yuxi People's Hospital, Affiliated
      with the Kunming Medical College, Yuxi dDepartment of Pharmacy, Ren Ji Hospital, 
      School of Medicine, Shanghai Jiaotong University eDepartment of Hematology, Ren
      Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University,
      Shanghai, China.
FAU - Liu, Maobai
AU  - Liu M
FAU - Li, Te
AU  - Li T
FAU - Lin, Houwen
AU  - Lin H
FAU - Zhong, Hua
AU  - Zhong H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0
      (4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3
      -ylpyrimidin-2-yl)amino)benzamide)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - RBZ1571X5H (Dasatinib)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*economics
MH  - China
MH  - Chronic Disease
MH  - Cost-Benefit Analysis
MH  - Dasatinib/administration & dosage/*economics
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Health Care Costs
MH  - Humans
MH  - Imatinib Mesylate/administration & dosage/*economics
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/*economics
MH  - Markov Chains
MH  - Models, Economic
MH  - Protein Kinase Inhibitors/administration & dosage/economics
MH  - Pyrimidines/administration & dosage/*economics
MH  - Quality-Adjusted Life Years
MH  - Treatment Outcome
EDAT- 2017/07/21 06:00
MHDA- 2017/07/29 06:00
CRDT- 2017/07/21 06:00
AID - 10.1097/MD.0000000000007445 [doi]
AID - 00005792-201707210-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(29):e7445. doi: 10.1097/MD.0000000000007445.